André-Guy Martin
Chercheur associé
Axe Oncologie
Publications
Voir tout-
article Niazi T, Nabid A, Malagon T, Tisseverasinghe S, Bettahar R, Dahmane R, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M
Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial
Eur Urol 87 (3), 2025.
-
article Nabid A, Carrier N, Martin AG, Bahary JP, Vavassis P, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, Souhami L
Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial
Qual Life Res 34 (3), 2025.
-
article Niazi T, Nabid A, Malagon T, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Igidbashian L, Bahoric B, Archambault R, Villeneuve H, Tsui JMG, Mohiuddin M
Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinair…
Int J Radiat Oncol Biol Phys 118 (1), 2024.
Projets
- The impact of Monte Carlo dose calculations on prostate and breast low-dose rate brachytherapy dose-outcome relationships and radiobiological modeling, du 2020-10-01 au 2025-09-30
- Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer (2SHARP), du 2025-03-14 au 2027-03-13
- Création de la base de données intégrée PRECISE-LDR (PRostatE Cancer Integrated data SEt-LDR), du 2025-04-01 au 2028-04-01
- A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN), du 2022-04-01 au 2025-02-28
- 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , du 2024-06-19 au 2025-03-31